Literature DB >> 15515135

Lipid-mediated siRNA delivery down-regulates exogenous gene expression in the mouse brain at picomolar levels.

Zahra Hassani1, Gregory F Lemkine, Patrick Erbacher, Karima Palmier, Gladys Alfama, Carine Giovannangeli, Jean-Paul Behr, Barbara A Demeneix.   

Abstract

BACKGROUND: Efficient in vivo vectors are needed to exploit the enormous potential of RNA interference (RNAi). Such methods require optimisation for specific delivery routes, tissues and usages. We tested the capacity of different non-viral vectors and formulation methods for inhibition of exogenous (luciferase) gene expression when used to introduce small interfering RNA (siRNA) into the mouse brain in vivo.
METHODS: Polyethylenimine (PEI)-based polyplexes and JetSI (a mixture of cationic lipids)-based lipoplexes were used to vectorise plasmid DNA encoding the firefly Photinus pyralis luciferase gene and picomolar amounts of siRNA directed against this gene. Two controls were used, DNA encoding an unrelated luciferase from Renilla reniformis and a mutated siRNA sequence.
RESULTS: First, we found that linear PEI, although efficient for delivering nucleic acids to cells, did not permit development of siRNA activity within the dose range tested (<0.5 pmol). Second, various combinations of cationic lipids were tried and the best formulation was found to be a combination of JetSI with the fusogenic lipid dioleoylphosphatidylethanolamine (DOPE). Efficient inhibition of target, firefly luciferase was obtained with exceedingly low amounts of siRNA: 78 +/- 6% inhibition at 24 h post-transfection with 0.2 pmol siRNA. This inhibition was dose-dependent and specific. No effect was seen on the control gene, co-transfected Renilla luciferase, and the control mutated siRNA sequence had no effect on the targeted firefly luciferase.
CONCLUSIONS: We have optimised an efficient cationic lipoplex method for delivery of siRNA into the newborn mouse brain. Specific inhibition of exogenous target gene expression is obtained with picomolar amounts of siRNA. Copyright (c) 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15515135     DOI: 10.1002/jgm.659

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  50 in total

Review 1.  Oligonucleotide therapeutic approaches for Huntington disease.

Authors:  Dinah W Y Sah; Neil Aronin
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

2.  Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA).

Authors:  Michael J Wagner; Rahul Mitra; Mark J McArthur; Wallace Baze; Kirstin Barnhart; Sherry Y Wu; Cristian Rodriguez-Aguayo; Xinna Zhang; Robert L Coleman; Gabriel Lopez-Berestein; Anil K Sood
Journal:  Mol Cancer Ther       Date:  2017-03-06       Impact factor: 6.261

Review 3.  Nonviral delivery of synthetic siRNAs in vivo.

Authors:  Saghir Akhtar; Ibrahim F Benter
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

Review 4.  Optical imaging-guided cancer therapy with fluorescent nanoparticles.

Authors:  Shan Jiang; Muthu Kumara Gnanasammandhan; Yong Zhang
Journal:  J R Soc Interface       Date:  2009-09-16       Impact factor: 4.118

5.  Hypothalamic Sirt1 regulates food intake in a rodent model system.

Authors:  Işin Cakir; Mario Perello; Omar Lansari; Norma J Messier; Charles A Vaslet; Eduardo A Nillni
Journal:  PLoS One       Date:  2009-12-15       Impact factor: 3.240

6.  Intratracheal administration of a nanoparticle-based therapy with the angiotensin II type 2 receptor gene attenuates lung cancer growth.

Authors:  Atsushi Kawabata; Abdulgader Baoum; Naomi Ohta; Stephanie Jacquez; Gwi-Moon Seo; Cory Berkland; Masaaki Tamura
Journal:  Cancer Res       Date:  2012-03-02       Impact factor: 12.701

7.  Endocytosis and intracellular trafficking properties of transferrin-conjugated block copolypeptide vesicles.

Authors:  Uh-Joo Choe; April R Rodriguez; Brian S Lee; Scott M Knowles; Anna M Wu; Timothy J Deming; Daniel T Kamei
Journal:  Biomacromolecules       Date:  2013-04-26       Impact factor: 6.988

Review 8.  In vivo imaging of RNA interference.

Authors:  Hao Hong; Yin Zhang; Weibo Cai
Journal:  J Nucl Med       Date:  2010-01-15       Impact factor: 10.057

9.  Focal Scn1a knockdown induces cognitive impairment without seizures.

Authors:  Alex C Bender; Heather Natola; Christian Ndong; Gregory L Holmes; Rod C Scott; Pierre-Pascal Lenck-Santini
Journal:  Neurobiol Dis       Date:  2013-01-11       Impact factor: 5.996

10.  Establishment of a positive-readout reporter system for siRNAs.

Authors:  Wei-Li Liu; Douglas P Owen; Kerry D Fisher; Leonard W Seymour; Mark Stevenson
Journal:  J RNAi Gene Silencing       Date:  2009-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.